Similarly, the results of the Asian population subgroup analysis in the PEONY phase 3 randomized clinical trial also showed that compared with neoadjuvant trastuzumab and docetaxel, neoadjuvant pertuzumab and trastuzumab plus docetaxel therapy significantly increased the pCR rate of early or locally advanced HER-2-positive Asian breast cancer patients (Shao et al., 2020). Here, ERBB2 is linked to breast carcinoma.